Skip to main content

Advertisement

Table 2 Clinical characteristics and cell-staining characteristics of patients whose CTCs were evaluated by ImageStreamX

From: Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer

Patient ID Prior therapies* PSA (ng/mL) EpCAM + Events CTCs (%) Mean AR intensity#(STDev) Median AR intensity#(Range) AR-high CTCs (%) Mean SI (STDev) Median SI (Range)
12077 L, B 168.4 5 4 (80) 117262 (120651) 89033 (29879-322996) 5 (100) 0.67 (1.67) -0.09 (-0.43-3.55)
12076 L, B, K, A 41.16 115 114 (99) 337937 (286897) 253104 (-6509-1427349) 108 (94) -0.12 (0.85) -0.25 (-1.79-2.31)
12079 L, B, S 32.24 104 96 (92) 25456 (36815) 11486 (1096-193627) 63 (61) 0.72 (1.06) 0.57 (-0.78-4.27)
12078 L, B, K 11.12 33 27 (82) 3202 (12736) 216 (-9849-56081) 5 (15) 0.97 (1.21) 0.95 (-0.98-2.06)
12080 L, B, D, C, A, E 554 0 NA NA NA NA NA NA
12081 L, D, C 275.4 36 24 (67) 33078 (58419) 4115 (-12080-240098) 16 (44) -0.05 (1.51) -0.44 (-1.77-3.79)
12082 B, S 5.78 18 11 (61) 59487 (213913) 1437 (-6856-913784) 6 (33) 0.39 (0.94) 0.21 (-0.62-1.64)
12083 L, B, A, E 522.3 12 11 (92) 38260 (29857) 30748 (3725-92097) 9 (75) 0.3 (1.11) -0.21 (-0.98-2.39)
12084 L 164.1 24 16 (67) 78782 (214426) 795 (-5122-800180) 8 (33) 0.6 (1.6) 0.17 (-1.02-3.63)
12081 L, D, C 382.6 15 5 (33) -2323 (4049) -2592 (-10466-4384) 0 NA NA
12079 L, B, S 39.3 0 NA NA NA NA NA NA
12086 B, L, K, D, A, E, Sa 1152 121 116 (96) 5674 (17971) 4256 (-13238-182505) 13 (11) 0.39 (0.66) 0.6 (-0.93-1.13)
12087 L, B 20.35 35 35 (100) -11351 (21968) -7673 (-68443-33422) 4 (11) -0.46 (0.63) -0.31 (-1.33-0.12)
12086 B, L, K, D, A, E, Sa 1320 11 11 (100) 115581 (88954) 102918 (46540-360131) 11 (100) -0.36 (0.44) -0.45 (-0.9-0.64)
12088 L, B, D 0.06 21 18 (86) 254074 (980505) 3184 (-1368-4502881) 4 (19) -0.2 (2.65) 0.99 (-4.17-1.38)
12028-101 L, B, D, A, E 37.23 50 48 (96) 241547 (1561372) 4910 (-3059-11054469) 12 (24) 0.58 (1.51) 0.35 (-1.88-3.73)
12064-102 L, B, K, A, C 6.33 4 3 (75) 55055 (63046) 44257 (1328-130379) 2 (50) 3.74 (0.35) 3.74 (3.49-3.99)
12072-103 B, L, A, D 20.59 220 215 (98) 21851 (48606) 7965 (-45736-465037) 92 (42) -0.1 (0.64) -0.17 (-1.2-2.06)
12080-104 L, B, D, C, A, E 1040 3 2 (67) 81694 (72851) 108774 (-819-137127) 2 (67) 2.36 (0.43) 2.36 (2.06-2.67)
14093 Ci/Et, To, Et/Te 1.83 7 6 (86) 5566 (12133) 2578 (-8042-29243) 2 (29) -0.12 (0.36) -0.12 (-0.38-0.13)
12027-105 L, B, N, K, D/Da, A, E, R 489.8 40 40 (100) 7995 (31246) 3127 (-62338-124132) 5 (13) 1.32 (0.87) 1.65 (0.3-2.34)
14093 Ci/Et, To, Et/Te 1.98 23 22 (96) 500281 (2345906) 3774 (-9141-11261273) 8 (35) -0.33 (1.54) 0.06 (-3.94-1.17)
12064-102 L, B, K, A, C 6.84 411 408 (99) 11281 (21967) 7020 (-6031-267789) 115 (28) 0.74 (0.52) 0.8 (-0.75-1.82)
12072-103 B, L, A, D 25.8 30 30 (100) 12437 (37826) 4871 (-19268-203291) 8 (27) 0.34 (0.68) 0.19 (-0.29-1.78)
12088 L, B, D 0.06 100 99 (99) 5505 (15912) 1670 (-13453-118622) 13 (13) 0.01 (0.61) -0.17 (-0.89-1.3)
14092 L, B, K, N, A, R 498.7 13 11 (85) 51770 (97952) 689 (-60783-230484) 5 (38) 1.86 (0.82) 2.03 (0.48-2.6)
12028-101 L, B, D, A, E 46.31 29 27 (93) 23411 (69628) 4050 (-5317-359215) 7 (24) 0.92 (1.22) 0.37 (-0.62-2.85)
12076-106 L, B, K, A, D 9.33 59 59 (100) 29569 (74779) 9686 (-24144-356079) 29 (49) 1.09 (0.65) 1.05 (-0.11-3.43)
14090 L, B, N, S, A 6.81 10 8 (80) 41168 (90507) -4692 (-83596-201844) 4 (40) 2.38 (0.52) 2.38 (1.76-3.02)
14089 L, B 5.06 11 9 (82) 192342 (687361) -2246 (-149355-2254943) 3 (27) 2.33 (1.29) 1.71 (1.47-3.82)
14089 L, B 5.87 8 2 (25) 1953000 (5025861) 218121 (-25632-14383254) 6 (75) 1.02 (1.71) 1.53 (-2.35-2.49)
  1. Thirty-one blood draws from 20 patients were evaluated by ImageStreamX technology, of which 29 blood draws from 20 patients had CTCs identified. SI = similarity index.
  2. *Prior therapies: A = abiraterone, B = bicalutamide, C = cabazitaxel, Ci = cisplatin, D = docetaxel, Da = dasatinib, E = enzalutamide, Et = etoposide, K = ketoconazole, L = LHRH agonist, N = nilutamide, R = radium223, S = sipuleucel-T, Sa = samarium, Te = temozolemide, To = topotecan.
  3. #Negative values are due to compensation within ImageStreamX.